commercial-stage-biopharma
(2)
Paratek Pharmaceuticals
Paratek Pharmaceuticals is a Boston-based commercial-stage biopharmaceutical company built on tetracycline chemistry to fight drug-resistant bacterial infections. Its flagship antibiotic NUZYRA (omadacycline) is a once-daily oral and IV broad-spectrum drug approved by the FDA in 2018 for community-acquired bacterial pneumonia and acute skin infections, and it is also being developed under a major BARDA contract as a national-stockpile countermeasure against pulmonary anthrax. Paratek also originated SEYSARA (sarecycline) for acne. Now privately held by Gurnet Point Capital and Novo Holdings after a 2023 acquisition, the company positions itself as a defender of public health against the slow-moving pandemic of antimicrobial resistance.
Phathom Pharmaceuticals
Phathom Pharmaceuticals is a commercial-stage biopharmaceutical company built around vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB) it licensed from Takeda in 2019 for the U.S., Europe and Canada. Its lead product, VOQUEZNA, won FDA approval in late 2023 - the first major innovation in U.S. GERD treatment in over 30 years - and is sold for non-erosive and erosive GERD plus H. pylori infection via its DUAL PAK and TRIPLE PAK regimens. The company reached $175.1 million in net revenue in 2025 and expects operating profitability in 2026.